Literature DB >> 27061530

Is helical tomotherapy-based intensity-modulated radiotherapy feasible and effective in bilateral synchronous breast cancer? A two-center experience.

Kemal Ekici1, Tumay Gokce, Ilker Karadogan, Aysun Fatma Eraslan, Cimen Akcay, Oztun Temelli, Eda Kaya Pepele, Funda Durmus Manalp, Caglar Keles, Arpaslan Mayadagli.   

Abstract

PURPOSE: This study describes the early clinical results and dosimetric parameters of intensity-modulated radiation therapy (IMRT) using a tomotherapy device in patients with primary bilateral synchronous breast cancer (PSBBC).
METHODS: Fourteen patients with bilateral breast cancer were treated with tomotherapy between January 2011 and October 2014. The treatment planning objectives were to cover 95% of the planning target volume using a 95% isodose, with a minimum dose of 90% and a maximum dose of 107%. The organs at risk (OAR), such as the lungs, heart, esophagus and spinal cord, were contoured. Acute toxicity was recorded during and after radiation therapy.
RESULTS: The advantages included better treatment conformity with lower dosages to minimize the risk to susceptible organs, such as the lungs, heart and spinal cord. There was improved coverage of the planning target volume, including the regional nodes, without any field junction problems. The median homogeneity index was 0.13 and the median conformity index 1.32. The median V20, V15, V10 and V5 for the total lungs were 18.5, 23.3, 24.2 and 60%, respectively. Skin acute toxicity was grade 1 in 72% and grade 2 in 14% of the patients. Esophageal acute toxicity was grade 1 in 43% of the patients.
CONCLUSION: Tomotherapy delivers treatment that is well-tolerated, with high homogeneity and coverage indexes and the capability to reduce the irradiation dose received by the lungs and heart in PSBBC patients. This technique is therefore feasible and safe for the treatment of bilateral breast cancer.

Entities:  

Mesh:

Year:  2016        PMID: 27061530

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  4 in total

1.  First clinical report of helical tomotherapy with simultaneous integrated boost for synchronous bilateral breast cancer.

Authors:  Tabassum Wadasadawala; Shanu Jain; Siji Paul; Reena Phurailatpam; Kishore Joshi; Palak Popat; Sandip Tandon; Aruna Alahari; Rajiv Sarin
Journal:  Br J Radiol       Date:  2017-07-14       Impact factor: 3.039

2.  Synchronous bilateral breast cancer irradiation: clinical and dosimetrical issues using volumetric modulated arc therapy and simultaneous integrated boost.

Authors:  Alba Fiorentino; Rosario Mazzola; Stefania Naccarato; Niccolò Giaj-Levra; Sergio Fersino; Gianluisa Sicignano; Umberto Tebano; Francesco Ricchetti; Ruggero Ruggieri; Filippo Alongi
Journal:  Radiol Med       Date:  2017-02-21       Impact factor: 3.469

3.  Comparison of Helical Tomotherapy and Direct Tomotherapy in Bilateral Whole Breast Irradiation in a Case of Bilateral Synchronous Grade 1 and Stage 1 Breast Cancer.

Authors:  Valentina Lancellotta; Martina Iacco; Elisabetta Perrucci; Claudio Zucchetti; Anna Concetta Dipilato; Lorenzo Falcinelli; Isabella Palumbo; Cynthia Aristei
Journal:  Am J Case Rep       Date:  2017-09-22

4.  Correlation between toxicity and dosimetric parameters for adjuvant intensity modulated radiation therapy of breast cancer: a prospective study.

Authors:  David Pasquier; Benoit Bataille; Florence Le Tinier; Raoudha Bennadji; Hélène Langin; Alexandre Escande; Emmanuelle Tresch; Franck Darloy; Damien Carlier; Frederik Crop; Eric Lartigau
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.